Viewing nowCombinationDucanova Tablets 60/2.5 mg (Pimasartan, Esamlodipine)
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.

MFDS item code 202300115 · Approved 2023.01.06 · Insurance code 694003950
Treatment of essential hypertension not controlled with fimasartan monotherapy
This medication can be used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with pimasartan potassium. It helps to effectively lower blood pressure to prevent cardiovascular complications and improve health.
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using fimasartan. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams as monotherapy. ㆍ 60/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy. ㆍ 60/5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy or this medicine 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. Elderly patients No initial dose adjustment is required for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). However, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 milligrams in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine in pediatric and adolescent patients aged 18 years or younger have not been established.
This medication can cause serious harm or death to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters; therefore, discontinue immediately upon confirmation of pregnancy. This medication should not be used in individuals with an allergy to its ingredients, pregnant or nursing women, patients on renal dialysis, patients with moderate to severe liver impairment, patients with biliary obstruction, patients with specific kidney diseases, patients with lactose intolerance, patients with severe aortic stenosis, and patients in shock. Particularly cautious use is advised for patients with low blood volume or salt, impaired renal function, renal artery hypertension, specific heart conditions, the elderly, etc., and administration should be under careful observation. Taking this medication may cause side effects such as dizziness, headache, facial or peripheral edema, urinary disorders, insomnia, flushing, etc., hence consult a physician if unusual symptoms persist or worsen. Patients with low blood pressure or electrolyte imbalances are at particular risk of excessively low blood pressure during initial dosing, so caution is required, and appropriate measures should be taken if necessary. This medication may interact with other antihypertensives or potassium-sparing diuretics, so inform the healthcare provider of any other medications being taken. Pregnant or nursing women should consult a physician before using this medication, and if breastfeeding, it is recommended to either halt breastfeeding or discontinue the medication. The safety and efficacy of this medication in children under 18 years of age have not been established, hence use is not recommended. Overdose may result in serious symptoms such as lowered blood pressure and heart rhythm abnormalities, requiring immediate medical attention.
Dizziness, postural dizziness, headache, facial swelling, peripheral edema, urination disorder, insomnia, flushing, syncope, sedation, migraine, dyspepsia, vomiting, nausea, upper abdominal pain, weakness, foreign body sensation, elevated liver enzyme levels, reduced platelet count, increased serum creatine phosphokinase, cough, muscle contractions, musculoskeletal rigidity, pruritus, localized urticaria, facial flushing, erectile dysfunction, epilepsy, amyotrophic lateral sclerosis, neuropathy, neuritis, facial paralysis, normal pressure hydrocephalus, spinal stenosis, acute pancreatitis, bowel obstruction, hemorrhagic duodenal ulcer, appendicitis, hemorrhoids, abdominal pain, intracranial hemorrhage, transient ischemic attack, atherosclerosis, deterioration of cerebral infarction, cerebral hemorrhage, liver cancer, colorectal neoplasm, neoplasm of unknown origin, cervical cancer, prostate cancer, acute kidney failure, chronic kidney failure, kidney stones, pyelonephritis, urinary incontinence, rhinitis, pulmonary fibrosis, pharyngitis, pneumonia, lung disease, death, exacerbation of low back pain, osteoarthritis, arthropathy, hypoglycemia, hyperkalemia, pulmonary embolism, purpura, bradycardia, atrial fibrillation, heart failure, hypertension, acute hepatitis, benign pituitary neoplasm, otitis media, pelvic organ prolapse, recurrent cancer, fracture, chest pain, weakness, fatigue, pain, weight gain, weight loss, hypotension, vasculitis, tension increase, sensory decrease, sensory abnormality, peripheral neuropathy, taste disorder, tremor, extrapyramidal disorder, gynecomastia, change in bowel habits, dry mouth, gastritis, gingival hypertrophy, pancreatitis, hyperglycemia, muscle cramps, myalgia, leukopenia, thrombocytopenia, mood changes, dyspnea, hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis, tinnitus, visual disturbances, increased urinary frequency, nocturia, hepatitis, jaundice, pruritus, rash, angioedema, erythema multiforme, myocardial infarction, arrhythmia, chest pain, hypotension, sinus block, atrioventricular block, abdominal discomfort, epigastric pain, diarrhea, loose stools, constipation, skin erythema, maculopapular rash, heaviness, warmth sensation, decreased glucose tolerance, frailty, symptoms of hypotension due to blood volume and sodium depletion, hyperkalemia, increased serum creatinine, increased blood urea, acute renal failure, hypotension, syncope, hyperkalemia, decreased kidney function, lowered blood pressure, shock symptoms, loss of consciousness, dyspnea, severe hypotension, pulmonary edema, blood pressure fluctuations, elevated blood pressure, purpura, fatty liver, intestinal vascular edema after angiotensin II receptor antagonist use, abdominal pain, nausea, vomiting, diarrhea
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that blocks light, and it is best to store it at room temperature between 1 and 30 degrees Celsius.
Yellow, round-edged quadrilateral film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.